81
edits
ICD Primary prevention trials: Difference between revisions
no edit summary
Secretariat (talk | contribs) No edit summary |
Secretariat (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
! Main Finding | ! Main Finding | ||
|- | |- | ||
| MADIT I< | | MADIT I<cite>35</cite> | ||
| Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III | | Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III | ||
| align="center" | 196 | | align="center" | 196 | ||
| Line 20: | Line 20: | ||
mortality with ICD (''P''=0.009); absolute RR 23% | mortality with ICD (''P''=0.009); absolute RR 23% | ||
|- | |- | ||
| CABG-PATCH< | | CABG-PATCH<cite>36</cite> | ||
| EF <35%, abnormal SAECG, elective CABG | | EF <35%, abnormal SAECG, elective CABG | ||
| align="center" | 900 | | align="center" | 900 | ||
| Line 28: | Line 28: | ||
|- | |- | ||
| MUSTT< | | MUSTT<cite>37</cite> | ||
| Prior MI, EF ≤40%, NSVT, inducible VT on EPS | | Prior MI, EF ≤40%, NSVT, inducible VT on EPS | ||
| align="center" | 704 | | align="center" | 704 | ||
| Line 36: | Line 36: | ||
|- | |- | ||
| MADIT II< | | MADIT II<cite>39</cite> | ||
| Prior MI≤1 month, EF≤30%, NYHA class I–III | | Prior MI≤1 month, EF≤30%, NYHA class I–III | ||
| align="center" | 1232 | | align="center" | 1232 | ||
| Line 44: | Line 44: | ||
|- | |- | ||
| DINAMIT< | | DINAMIT<cite>38</cite> | ||
| Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III | | Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III | ||
| align="center" | 674 | | align="center" | 674 | ||
| Line 52: | Line 52: | ||
|- | |- | ||
| SCD-HeFT< | | SCD-HeFT<cite>34</cite> | ||
| EF≤35%, (ischemic or nonischemic) NYHA class II–III | | EF≤35%, (ischemic or nonischemic) NYHA class II–III | ||
| align="center" | 2521 | | align="center" | 2521 | ||
| Line 63: | Line 63: | ||
|} | |} | ||
==References== | |||
<biblio> | |||
#34 Bardy G, Lee KL, Mark D, Poole J, Packer D, Boineau R, Domanski M, Troutman R, Anderson J, Johnson G, McNulty S, Clapp-Channing N, Davidson-Ray L, Fraulo E, Fishbein D, Luceri R, Ip J. Amiodarone or an implantable cardioverter- defibrillator for congestive heart failure. ''N Engl J Med.'' 2005;352:225–237. | |||
#35 Moss A, Hall W, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. ''N Engl J Med.'' 1996;335:1933–1940. | |||
#36 Bigger J; Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. ''N Engl J Med.'' 1997;337:1569 –1575. | |||
#37 Buxton A, Lee K, DiCarlo L, Gold M, Greer G, Prystowsky E, O’Toole M, Tang A, Fisher J, Coromilas J, Talajic M, Hafley G; Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. ''N Engl J Med.'' 2000;342:1937–1945. | |||
#38 Hohnloser S, Kuck KH, Dorian P, Roberts R, Hampton J, Hatala R, Fain E, Gent M, Connolly S; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. ''N Engl J Med.'' 2004;351:2481–2488. | |||
#39 Moss A, Zareba W, Hall W, Klein H, Wilber D, Cannom D, Daubert J, Higgins S, Brown M, Andrews M; for the MADIT II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. ''N Engl J Med.'' 2002;346:877–883. | |||
</biblio> | |||